
Product Data Sheet

Product Name: KY-02327 acetate

Cat. No.: GC65356

Chemical Properties

Cas. No. 2989396-34-9

Formula C₂₂H₃₁N₃O₆

M.Wt 433.5

Solubility DMSO : 50 mg/mL (115.34 mM); ultrasonic and warming and heat to 60°C)

Storage 4°C, away from moisture and light

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Background

KY-02327 acetate, a metabolically stabilized KY-02061 analog, is a potent Dishevelled (Dvl)-CXXC5 interaction inhibitor. KY-02327 acetate shows an activating effect on the Wnt/ β -catenin pathway, resulting in promotion of osteoblast differentiation[1].

KY-02327 (1-10 μ M; 2 days; MC3T3E1 cells, a murine pre-osteoblast cell line) acetate increases β -catenin protein level together with Runx2 and accumulated nuclear β -catenin in a dose-dependent manner[1]. KY-02327 (1-10 μ M) acetate increases the mRNA levels of osteoblast differentiation markers collagen 1a (Col1a) and osteocalcin (OCN) [1].

KY-02327 (20 mg/kg; p.o.; 5 sequential days per week for 4 weeks) acetate successfully rescues bone loss in the ovariectomized (OVX) mouse model[1].

[1]. Kim HY, et al. Small molecule inhibitors of the Dishevelled-CXXC5 interaction are new drug candidates for bone anabolic osteoporosis therapy. EMBO Mol Med. 2016;8(4):375-387.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA